Etomoxir sodium salt

Catalog No.S8244 Synonyms: (R)-(+)-Etomoxir sodium salt

For research use only.

Etomoxir sodium salt ((R)-(+)-Etomoxir sodium salt) is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) on the outer face of the inner mitochondrial membrane. Etomoxir enhances palmitate-induced cell apoptosis.

Etomoxir sodium salt Chemical Structure

CAS No. 828934-41-4

Selleck's Etomoxir sodium salt has been cited by 23 publications

Purity & Quality Control

Choose Selective CPT Inhibitors

Biological Activity

Description Etomoxir sodium salt ((R)-(+)-Etomoxir sodium salt) is an irreversible inhibitor of carnitine palmitoyltransferase-1 (CPT-1) on the outer face of the inner mitochondrial membrane. Etomoxir enhances palmitate-induced cell apoptosis.
CPT-1 [1] PPARα [1]
In vitro

Etomoxir has also been identified as a direct agonist of PPARα. Etomoxir is a compound that binds irreversibly to the catalytic site of CPT-1 inhibiting its activity, but also upregulates fatty acid oxidation enzymes. Transcriptional effects of etomoxir could be due to 1. shift in energy metabolism with increased glucose utilization and 2. PPARalpha activation[1]. Etomoxir reduces pro-inflammatory cyokine production and increases apoptosis of MOG specific T cells[2]. Etomoxir has been shown to decrease oxygen consumption rates (OCRs) and impair ATP and NADPH production in the pediatric glioblastoma cell line SF188[3].

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KB cells M4\3ZWN6fG:2b4jpZ4l1gSCjc4PhfS=> NWmxV|VNS3m2b4TvfIlkcXS7IHnuJIh2dWGwIFvCJINmdGy|LDDJR|UxRTJwN{[g{txO NUjvb2E2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG1NFQyPTZpPkKxOVA1OTV4PD;hQi=>
U251 NVXUepFHT3Kxd4ToJIlvcGmkaYTvckBie3OjeR?= NGTtPWk2OCEQvF2= MYe3Nk1pKHS{ZXH0cYVvfHNiaHH2[UB{dGmpaISg[5Jwf3SqIHnubIljcXSxcomg[YZn\WO2cx?= MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODV5NECyNEc,OzB3N{SwNlA9N2F-
U87 NX7SOot7T3Kxd4ToJIlvcGmkaYTvckBie3OjeR?= NX\FXYh3PTBizszN MmDQO|IucCC2cnXheI1mdnS|IHjheoUhe2yrZ3j0JIdzd3e2aDDpcohq[mm2b4L5JIVn\mWldIO= NGiw[VM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEW3OFAzOCd-M{C1O|QxOjB:L3G+
U373-U MX3Hdo94fGhiaX7obYJqfG:wIHHzd4F6 NVi1cXRbPTBizszN NYTsellSPzJvaDD0doVifG2nboTzJIhifmVic3zp[4h1KGe{b4f0bEBqdmirYnn0c5J6KGWoZnXjeJM> Mnm3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB3N{SwNlAoRjNyNUe0NFIxRC:jPh?=
MCF-7 cells MX3GeY5kfGmxbjDhd5NigQ>? NH:zb2kx6oDVMkCw5qCw|ryP NVq1UGg{PCCq NUn0PWVxcW5iZHKtZ2FOWC2neIDvd4VlKGOnbHzzJGVVVyClYYXz[YQh[SCvZYThZo9tcWNiaX3iZYxidmOn MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODl6MUe0NEc,OzB7OEG3OFA9N2F-
HepG2 cells NFLzfFZHfW6ldHnvckBie3OjeR?= M4OyT|I1KGh? NVriU|dLTXSxbX;4bZIhe2mpbnnmbYNidnSueTDpcohq[mm2czDwZYxucXSjdHWgcYV1[WKxbHnzcUB4cXSqIHHuJGlEPTBiaX6geIhmKG6jbn;tc4xieiC{YX7n[U4> MkO4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl5NECzNVQoRjJ7N{SwN|E1RC:jPh?=
Methods Test Index PMID
Western blot p-ERK / p-p38 / p-JNK / p-FoxO4 ; p21 / FoxO1 / FoxO3a ; p-mTOR(S2448) / mTOR / p-S6K(T389) / p-4EBP1 / p-BAD(S112) / cleaved PARP ; p-ACC2 / p-AMPK / AMPK 26716645 25122071
In vivo Etomoxir has a protective action on the ischemia/reperfusion injury of the kidney similarly to an established PPARalpha agonist. It has been developed for treating non-insulindependent diabetes mellitus. Etomoxir increases the functional recovery of fatty acid perfused ischemic rat hearts which is unrelated to changes in levels of long-chain acylcarnitines and is attributed to an increased glucose use. A chronic treatment of rats with etomoxir increases the SR Ca2+-ATPase activity, the Ca2+ uptake rate, the number of active Ca2+ pumps E~P, the SERCA2 protein and the SERCA2 mRNA abundance of the heart. At a low dosage, etomoxir has a selective influence on the rate of contraction and relaxation of overloaded hearts. Etomoxir, in the liver can act as peroxisomal proliferator, increasing DNA synthesis and liver growth[1]. Etomoxir-treated mice displays a reduced immune cell infiltration in the CNS with few macrophages, activated microglia, or T cells present. Etomoxir reduces inflammation and demyelination in the CNS of treated mice[2]. Inhibition of fatty acid oxidation by etomoxir prolongs survival time in a syngeneic mouse model of malignant glioma and slow tumor growth. Emergence and progression of glioma are delayed upon treatment with the investigational drug etomoxir. Etomoxir has already been tested in phase I/II clinical trials for treating moderate congestive heart failure; this trial is discontinued because 4 patients (of 226 taking the drug) developed unacceptably high liver transaminase levels upon treatment, and the risk of such drastic side effects is deemed sufficient to negate the potential benefit of this drug for these patients[3].

Protocol (from reference)

Cell Research:


  • Cell lines: Splenocytes
  • Concentrations: 100 μM
  • Incubation Time: 72 h
  • Method:

    C57BL/6 mice are immunized with 200 μg MOG35-55 peptide s.c., and 14 days later splenocytes are isolated and cultured at a concentration of 6×106 cells/ml in DMEM containing high (4.5 g/L) or low (1 g/L) glucose, 10% FBS 50 μg/ml MOG peptide, and 25 ng/ml IL-12 (R&D systems, Minneapolis, MN) in the presence of vehicle or 100 μM etomoxir. 72 hours later cells are harvested for APO-BrdU staining and supernatants collected for IL-4, IL-17 and IFN-γ ELISA. (MOG:myelin oligodendrocyte glycoprotein)

Animal Research:


  • Animal Models: C57BL6/J mice
  • Dosages: 15 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

Chemical Information

Molecular Weight 320.74


CAS No. 828934-41-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1C(O1)(CCCCCCOC2=CC=C(C=C2)Cl)C(=O)[O-].[Na+]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Etomoxir sodium salt | Etomoxir sodium salt supplier | purchase Etomoxir sodium salt | Etomoxir sodium salt cost | Etomoxir sodium salt manufacturer | order Etomoxir sodium salt | Etomoxir sodium salt distributor